NervGen Pharma Corp. (NASDAQ:NGEN) stock is trading higher Tuesday morning after the clinical-stage biopharmaceutical company announced positive independent, blinded biomechanical gait analyses from its Phase 1b/2a CONNECT SCI study.

Genuine Neural Recovery Demonstrated

The Vancouver-based company reported that its lead therapeutic candidate, NVG-291, demonstrated a statistically significant improvement in gait quality (p=0.0197) for chronic spinal cord injury patients.

The analyses, conducted by AI-powered movement intelligence company Newton Tech on Tuesday, focused on three established hallmarks of true neural repair: coordination, mechanical effort and postural stability.

Perfect Responder Rate Highlights Data

According to the Global Statistical Test used in the study, 100% (10 out of 10) of the subjects treated with NVG-291 were classified as responders across the composite recovery measures. In comparison, only 10% (1 out of 10) of the placebo group qualified as responders (p=0.0001).

“The multi-domain biomechanical signature reported here is precisely the pattern one would hope to find from a therapy enabling true underlying neural recovery,” stated Armin Curt, Clinical Director of the SCI Center at Balgrist University Hospital.

NervGen CEO Adam Rogers noted Tuesday that these findings “further reinforce the foundation upon which we are advancing NVG-291 into the Phase 3 RESTORE registrational study in chronic tetraplegia.” The company remains on track to initiate the Phase 3 study in mid-2026.

NGEN Stock: Key Levels and Momentum Indicators

At $2.16, the stock is trading 40.8% below its 20-day SMA ($3.65), 44% below its 50-day SMA ($3.86), and 44.6% below its 100-day SMA ($3.90), which keeps overhead supply in focus on any rally.

The more constructive datapoint is the longer-term reference: the stock is trading 9.3% above its 200-day SMA ($1.98), so the $2 area is acting like a line in the sand that bulls want to defend.

The moving-average stack is still mixed, with the 20-day SMA below the 50-day SMA (bearish), but the 50-day SMA remains above the 200-day SMA, which is a longer-term positive if price can reclaim the shorter averages.

  • Key Resistance: $3.65 — the 20-day SMA is the nearest overhead trend level and a logical first test if the rebound extends
  • Key Support: $1.98 — the 200-day SMA sits just below current price and lines up with the broader $2 pivot zone

NGEN Price Action: NervGen Pharma shares were up 5.29% at $2.19 during premarket trading on Tuesday, according to Benzinga Pro data.

Photo via Shutterstock